What Are Vascepa Rebate Restrictions?
Vascepa (icosapent ethyl), made by Amarin, faces rebate restrictions under Medicaid's best price rules. These limit how much Amarin can discount the drug to commercial payers without triggering a lower "best price" that forces steep Medicaid rebates, often 23% or more of the drug's price.[1]
Why Do These Restrictions Exist for Vascepa?
The restrictions stem from Vascepa's 2020 FDA approval expansion to reduce cardiovascular risk in broad patient groups (the REDUCE-IT label). Before this, under the narrower MARINE label for high triglycerides, Vascepa qualified for an orphan drug exclusion from best price calculations. The label change ended that exclusion, exposing Amarin to higher Medicaid liability. Amarin sued CMS in 2020, arguing the restrictions unlawfully inflate costs and limit patient access, but courts largely upheld CMS's position.[1][2]
How Do They Impact Pricing and Access?
Restrictions cap deep commercial rebates, keeping Vascepa's list price high—around $4,600 for a 30-day supply. This raises out-of-pocket costs for cash-pay patients and pushes payers toward cheaper alternatives like generic Lovaza. Amarin reported $1.1 billion in 2022 U.S. sales despite these hurdles, but net prices fell due to limited rebate flexibility.[1][3]
When Does Vascepa's Patent Protection End?
Key patents expire in 2034 (composition-of-matter) and 2039 (method-of-use for CV risk reduction), per DrugPatentWatch.com.[4] No generics are approved yet, but ANDA filings from Hikma and Dr. Reddy's face ongoing litigation. Exclusivity from the label expansion ended in 2026.
What Are Patient Assistance Options?
Amarin's CopayAssist program covers copays up to $15,000 annually for commercial insurance patients (income limits apply). Uninsured patients may get free Vascepa via the Patient Assistance Program. These bypass rebate rules but exclude government beneficiaries.[1]
How Does Vascepa Compare to Alternatives?
| Drug | Key Use | Monthly Cost (List) | Generic Available? |
|------|---------|---------------------|---------------------|
| Vascepa | CV risk + high triglycerides | ~$4,600 | No |
| Lovaza | High triglycerides only | ~$300 | Yes |
| generic fenofibrate | High triglycerides | ~$20 | Yes |
Patients often switch to generics post-restrictions, as payers favor lower-cost options without CV claims.[3]
Sources:
[1] Amarin Vascepa Site
[2] Amarin v. HHS Court Filings
[3] Amarin SEC Filings
[4] DrugPatentWatch.com - Vascepa Patents